comparemela.com

Latest Breaking News On - Helena edlund - Page 1 : comparemela.com

Amplifier Therapeutics Raises Additional Funding in Series A

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Helena edlundJames hallThomas edlundOlof karlssonEuropean unionAmplifier therapeuticsFuture venturesAmplifier seriesCambrian bio

Cambrian Biopharma: Cambrian Bio launches Amplifier Therapeutics to develop clinical-stage AMPK activator

The New York based biotech company announces launch of Amplifier Therapeutics to develop the clinical stage pan-AMPK activator, ATX-304 NEW YORK, March 14, 2023 /PRNewswire/ Cambrian

New yorkUnited statesDennis riedlThomas edlundJames peyerHelena edlundRuth thieroff ekerdtJames hallOlof karlssonRosa argyropoulosHead of cardiovascular business development at astrazenecaA distributed development companyGlobal corporate communicationsClinical developmentAmplifier therapeuticsCardiovascular business development

Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

/PRNewswire/ Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced the publication by co-founder Helena.

James hallAlice wallenbergs stiftelseFamiljen erling perssonsHelena edlundCentre for molecular medicineScientific reportsMolecular medicineHeart failureRenal diseaseBetagenon ab

Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

/PRNewswire/ Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced the publication by co-founder Helena.

James hallAlice wallenbergs stiftelseFamiljen erling perssonsHelena edlundCentre for molecular medicineScientific reportsMolecular medicineHeart failureRenal diseaseBetagenon ab

Betagenon AB: Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice

STOCKHOLM, Dec. 23, 2021 /PRNewswire/ Betagenon AB, a Sweden-based company focused on development of AMPK activator compounds, today announced the publication by co-founder Helena Edlund

James hallKostenloser wertpapierhandelAlice wallenbergs stiftelseFamiljen erling perssonsHelena edlundCentre for molecular medicineScientific reportsMolecular medicineHeart failureRenal disease

vimarsana © 2020. All Rights Reserved.